Bioventus Inc. (BVS)
| Market Cap | 474.86M |
| Revenue (ttm) | 563.83M |
| Net Income (ttm) | 10.17M |
| Shares Out | 66.98M |
| EPS (ttm) | 0.15 |
| PE Ratio | 46.17 |
| Forward PE | 9.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 321,955 |
| Open | 7.62 |
| Previous Close | 7.62 |
| Day's Range | 7.05 - 7.73 |
| 52-Week Range | 5.81 - 11.89 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 13.33 (+88.01%) |
| Earnings Date | Nov 4, 2025 |
About BVS
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spina... [Read more]
Financial Performance
In 2024, Bioventus's revenue was $573.28 million, an increase of 11.89% compared to the previous year's $512.35 million. Losses were -$33.54 million, -78.53% less than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BVS stock is "Buy." The 12-month stock price target is $13.33, which is an increase of 88.01% from the latest price.
News
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investig...
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Execu...
Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript
Bioventus Inc. ( BVS) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Dir...
Bioventus Reports Third Quarter Financial Results
DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for th...
Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to sha...
Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Bioventus Inc. (NASDAQ:BVS) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Mark Singleton - Senior VP & CFO Presentation Unknown Analyst T...
Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President a...
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Execu...
Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Crawford - Vice President of Investor Relations & Treasurer Mark L. Singleton - Senio...
Bioventus Reports Second Quarter Financial Results
DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the...
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into...
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Adm...
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Sin...
Bioventus Reports First Quarter Financial Results
DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the ...
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fin...
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark...
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
DURHAM, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full...
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully...
Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Sen...
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Executives Buying W. P. Carey And 2 Other Stocks
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.